rss
Br J Ophthalmol 2007;91:136-137 doi:10.1136/bjo.2006.107813
  • Editorial

The further refinement of ROP treatment. Commentary on the Early Treatment of Retinopathy of Prematurity study: structural findings at 2 years of age

  1. Alistair R Fielder1,
  2. Andrew R Wilkinson2
  1. 1Department of Optometry and Visual Science, City University, London, UK
  2. 2Neonatal Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK
  1. Correspondence to: Professor A R Fielder Department of Optometry and Visual Science, City University, Northampton Square, London EC1V 0HB, UK; a.fielder{at}city.ac.uk
  • Accepted 28 September 2006

Reaching the goal of early ROP treatment by recent advances in ROP management

The treatment of retinopathy of prematurity (ROP) continues to evolve, and it is good to see that earlier treatment at high-risk prethreshold ROP, compared with conventional management with treatment at threshold, improves the structural outcome, and that this is maintained at 2 years after intervention.1 It is also encouraging to note that there was no increase in adverse ocular outcomes by this earlier treatment. Owing to reclassification of some eyes which underwent vitreoretinal surgery, there was an increase in unfavourable structural outcome between 6 and 9 months, but thereafter they were similar in indicating an encouraging degree of ocular stability.

So far so good, but the revised indications for the treatment of ROP emanating from the Early Treatment of ROP (ETROP) randomised trial2 require a major change in clinical practice that must be incorporated into clinical guidelines. Unsurprisingly, these recommendations have generated considerable published3–7 and unpublished debate. This broadly centres on issues relating to the breaking down of the main ETROP cohort into subgroups based on zone, stage and the presence of plus disease. Concerns have been expressed that following the ETROP recommendations will result in unnecessary treatment of eyes that fall into one or more of the categories that might resolve spontaneously, notably zone II, stage 2+. This is not a trivial issue, as the outcome of these discussions will necessarily feed into clinical guidelines for ROP screening and treatment.

To get to the heart of the matter, we need to consider the concept of “threshold” ROP that was fundamental to the design of the CRYO-ROP study8 and is now firmly embedded in …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Services

  1. Email this link to a friend
  2. Alert me when this article is cited
  3. Alert me if a correction is posted
  4. Alert me when eletters are published
  5. Article Usage Statistics
  6. Similar articles in this journal
  7. Similar articles in Web of Science
  8. Similar articles in PubMed
  9. Add article to my folders
  10. Download to citation manager
  11. Request permissions

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.